A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A phase 3 trial of Venetoclax, Acalabrutinib and Obinutuzumab in chronic lymphocytic leukaemia, run by AbbVie, now recruiting.
Overview
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT06428019 by AbbVie, with 170 participants planned, started 2024-08-05 and due to reach its primary completion in 2028-03. Interventions recorded: Venetoclax, Acalabrutinib and Obinutuzumab.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Shares Obinutuzumab, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Acalabrutinib, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Shares Acalabrutinib, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Acalabrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Acalabrutinib, Chronic lymphocytic leukaemia and the tag pipeline.